Protein kinase C inhibition enhances platelet-activating factor-induced eicosanoid production in human eosinophils

被引:29
作者
Dent, G
Muñoz, NM
Rühlmann, E
Zhu, XD
Leff, AR
Magnussen, H
Rabe, KF
机构
[1] LVA Hamburg, Krankenhaus Grosshansdorf, Zentrum Pneumol & Thoraxchirurg, D-22927 Grosshansdorf, Germany
[2] Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA
[3] Univ Chicago, Comm Cell Physiol, Div Biol Sci, Chicago, IL 60637 USA
关键词
D O I
10.1165/ajrcmb.18.1.2817
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previous investigations have suggested that protein kinase C (PKC) may regulate guinea pig eosinophil responses through a suppressive "negative feedback" mechanism. Using the selective PI(C inhibitors bisindolylmaleimide I (Bis I, GF 109203X) and calphostin C, we examined the role of PKC in platelet activating factor (PAF)-induced respiratory burst and generation of arachidonic acid metabolites in human peripheral blood eosinophils, Ris I inhibited PAF-induced generation of superoxide anion with substantially lower potency (geometric mean IC50 = 1.41 mu M, 95% CI 0.94-2.11 mu M) than it exhibited against responses to the phorbol esters 4-beta-phorbol 12-myristate 13-acetate (PMA: IC50 = 0.25 mu M, 0.09-0.72 mu M; P < 0.01) and 4-beta-phorbol 12,13-dibutyrate (IC50 = 0.48 mu M, 0.20-1.14 mu M; P < 0.05). The production of thromboxane (measured as TxB(2)) induced by 1 mu M PAF was increased significantly by Bis Ist concentrations of 1 mu M (162 +/- 7.5% of control PAF response; P < 0.01) and 10 mu M (194 +/- 17%; P < 0.001): TxB(2) release induced by PMA was unaffected by concentrations of Bis I up to 1 mu M and inhibited by 10 mu M Bis I (48 +/- 11%; P < 0.05), Bis I (1 mu M) significantly increased both thromboxane and leukotriene C-4 (LTC4) production induced by 2 mu M (P < 0.01 and P < 0.05, respectively) or 20 mu M PAF (both P < 0.001). The actions of Bis I on PAF-stimulated thromboxane and leukotriene production were mimicked Dy a second PKC inhibitor, calphostin C, whereas the non-PKC-inhibitory analog, bisindolylmaleimide V, caused no enhancement of TxB(2) or LTC4 production, The increase in intracellular free calcium induced by 1 mu M PAF was heightened and prolonged in cells pre-treated with 1 mu M Bis I or 1 mu M calphostin C (peak increase, P < 0.05 for both drugs; level 60 s after addition of PAF, P < 0.001 and P < 0.05 for Bis I and calphostin C, respectively; time to return to 50% of peak, P < 0.05 for Bis I). We conclude that PI(C inhibition causes augmentation of thromboxane and LTC4 production in PAF-stimulated human eosinophils despite suppressing respiratory burst activity, indicating that different signaling pathways predominate hi these two responses and that PKC mediates a suppression of an early stage in an alternative pathway of activation.
引用
收藏
页码:136 / 144
页数:9
相关论文
共 28 条
[1]  
ALI A, 1994, J IMMUNOL, V153, P776
[2]   SELECTIVE INACTIVATION BY ENDOGENOUS PROTEIN KINASE-C OF HUMAN-PLATELET HIGH-AFFINITY GTPASE COUPLED WITH PAF RECEPTORS [J].
AVDONIN, PV ;
SVITINAULITINA, IV ;
TKACHUK, VA .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1989, 21 :139-143
[3]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[4]   REGULATION OF PLATELET-ACTIVATING FACTOR RECEPTOR AND PAF RECEPTOR-MEDIATED ARACHIDONIC-ACID RELEASE BY PROTEIN-KINASE-C ACTIVATION IN RAT KUPFFER CELLS [J].
CHAO, W ;
LIU, HL ;
HANAHAN, DJ ;
OLSON, MS .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1990, 282 (01) :188-197
[5]   INHIBITORS OF PROTEIN-KINASE-C .1. 2,3-BISARYLMALEIMIDES [J].
DAVIS, PD ;
HILL, CH ;
LAWTON, G ;
NIXON, JS ;
WILKINSON, SE ;
HURST, SA ;
KEECH, E ;
TURNER, SE .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (01) :177-184
[6]  
EVANS DJ, 1996, AM J RESP CRIT CARE, V153, pA57
[7]  
GIEMBYCZ MA, 1990, J IMMUNOL, V144, P3489
[8]  
HAMANN KJ, 1996, PULMONARY CRITICAL C, P355
[9]   AN IMPROVED IMMUNOMAGNETIC PROCEDURE FOR THE ISOLATION OF HIGHLY PURIFIED HUMAN BLOOD EOSINOPHILS [J].
HANSEL, TT ;
DEVRIES, IJM ;
IFF, T ;
RIHS, S ;
WANDZILAK, M ;
BETZ, S ;
BLASER, K ;
WALKER, C .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 145 (1-2) :105-110
[10]  
JACOBSON PB, 1995, J PHARMACOL EXP THER, V275, P995